Please assess the completion status of the following clinical trial:

Trial Title: Chloroquine Alone or in Combination for Malaria in Children in Malawi

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects aged greater than or equal to 6 months to 5 years presenting to Ndirande Health Centre with signs or symptoms consistent with malaria including, but not limited to, one or more of the following:~  1. fever at the time of evaluation (axillary temperature greater than or equal to 37.5 degrees Celsius by digital thermometer)~ 2. report of fever within the last two days~ 3. clinically profound anemia (conjunctival or palmar pallor)~ 4. headache~ 5. body aches~ 6. abdominal pain~ 7. decreased intake of food or fluids~ 8. weakness~* Weight greater than or equal to 5kg.~* Positive malaria smear for P. falciparum mono-infection with parasite density 2,000-200,000/mm\^3.~* Planning to remain in the study area for 1 year.~* Willingness to return for four-weekly routine visits, as well as unscheduled sick visits.~* Parental/guardian consent for each participant.~Exclusion Criteria:~* Signs of severe malaria: One or more of the following:~  1. hemoglobin less than or equal to 5 g/dL~ 2. prostration~ 3. respiratory distress~ 4. bleeding~ 5. recent seizures, coma or obtundation (Blantyre coma score \< 5)~ 6. inability to drink~ 7. persistent vomiting~* Known allergy or history of adverse reaction to chloroquine (CQ), artesunate, azithromycin, erythromycin or atovaquone-proguanil (AP)~* Chronic medication with any antibiotic or anti malarial medication~* Previous enrollment in this study~* Alanine aminotransferase (ALT) more than 5x the upper limit of normal or creatinine greater than 3x the upper limit of normal~* Evidence of chronic disease or physical stigmata of severe malnutrition (i.e., loss of muscle mass or subcutaneous tissue, edema, or skin or hair findings consistent with severe malnutrition)

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- CQ Monotherapy (Type: EXPERIMENTAL): N=160: treat with Chloroquine (CQ) alone.
- CQ plus atovaquone proguanil (Type: EXPERIMENTAL): N=160: treat with CQ plus atovaquone proguanil.
- CQ plus artesunate (Type: EXPERIMENTAL): N=160: treat with CQ plus artesunate.
- CQ plus azithromycin (Type: EXPERIMENTAL): N=160: treat with CQ plus azithromycin.

Based on this trial design, predict the completion outcome and termination type (if applicable).